Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus
| Autor: | Şazi Imamoğlu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Oral treatment General and Internal Medicine business.industry Type 2 Diabetes Mellitus Type 2 diabetes medicine.disease Gastroenterology Internal medicine medicine General Earth and Planetary Sciences Oral glucose business Type-2 diabetes oral treatment anti-diabetics Genel ve Dahili Tıp General Environmental Science |
| Zdroj: | Volume: 3, Issue: 1 1-5 Turkish Journal of Internal Medicine |
| ISSN: | 2687-4245 |
| Popis: | Type 2 diabetes is manifested by impaired insulin secretion in pancreatic beta cells, increased glucagon secretion in alpha cells, and generally has a history of insulin resistance. The treatment of glucose metabolism disorder and the resulting hyperglycemia constitute an important part of the treatment of type 2 diabetes. Glycemic targets can be targeted with A1C |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|